How do you manage patients who progress on AR targeted therapy and ADT started in mCSPC setting?
Does progression represent resistance to AR targeted therapy?
Or does progression leave open possibility for further meaningful response to switching the AR targeted therapy from enzalutamide or apalutamide to abiraterone or if abiraterone to daralutamide or enzalutamide or apalutamide?